Savara Craters as FDA Delays Decision for Lung Disease
Vandana Singh 12 hours ago
Trading IdeasMoversNewsFDAGeneralBiotechHealth Care
Savara (NASDAQ: SVRA) shares fell Friday after the FDA said it will miss its November 22, 2026 PDUFA target date for molgramostim.
Savara Inc. (NASDAQ:SVRA) shares tanked on Friday as the FDA will not meet its PDUFA target action date for the company’s molgramostim Biologics License Application (BLA), a company-specific setback that’s weighing on the stock even while Healthcare is up 1.03% (second-best sector) and the S&P 500 is down 0.95%.
Savara Stock Drops After FDA Misses Molgramostim PDUFA Date
The company said the FDA communicated that it will not take action by the November 22, 2026 PDUFA target date for the molgramostim inhalation solution BLA in autoimmune pulmonary alveolar proteinosis.
The company noted that the review is still ongoing. No revised action date was provided, which may create uncertainty around the timing of a potential approval decision.
PAP is a rare lung disorder where excess surfactant (proteins and lipids) builds up in the alveoli (air sacs). The buildup impairs oxygen transfer into the bloodstream.
SVRA Technical Analysis: Trend Still Bearish, Momentum Improving
From a longer-term trend perspective, the stock is still in a bearish structure: it’s trading below all major moving averages, including the 20-day SMA ($4.76), 50-day SMA ($4.86), 100-day SMA ($5.23), and 200-day SMA ($5.31).
That keeps rallies vulnerable to selling pressure near those averages, especially with the 20-day SMA below the 50-day SMA and the 50-day SMA below the 200-day SMA (the death cross that formed in September).
Analyst Consensus & Recent Actions:
The stock carries a Buy rating with an average price forecast of $10.00. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Price Forecast $10.00) (November 12)
- JP Morgan: Initiated with Overweight (Price Forecast $12.00) (October 7)
How Savara Ranks On Momentum In Benzinga Edge
Below is the Benzinga Edge scorecard for Savara, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Neutral (Score: 69.83) — Momentum is closer to the middle of the pack, suggesting the stock can still swing, but it isn’t consistently leading the market.
SVRA Stock Price Activity: Savara shares were down 18% at $4.27 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock
More on SVRA
FDA & biotech Benzinga
Savara Says FDA Will Not Meet PDUFA Target Action Date Of November 22 For Molgramostim Inhalation Solution BLA For Treatment Of Autoimmune PAP; No Revised Action Date Communicated By The FDASavara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it…
Analyst ratings Benzinga
HC Wainwright & Co. Maintains Buy on Savara, Lowers Price Target to $9HC Wainwright & Co. analyst Matthew Caufield maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $10 to $9.
